Evidence map›Paper›PMID 40500712›Full record

ArticleJournal of inflammation (London, England)2025

RhIL-11 reverses liver damage in septic mice by STAT3-mediated M-MDSCs induction modulated by a parallel mTORC1 signaling branch.

Yuefang Liu, Shujun Gao, Zhanghui Li, Lei Yin, Shiyao Ge, Yangjing Zhao, Hui Wang, Bing Wan, Qixiang Shao

Abstract read
In one paragraph

Article in Journal of inflammation (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuefang Liu *Institute of Medical Genetics and Reproductive Immunity, The Digestive and Reproductive System Cancers Precise Prevention Engineering Research Center of Jiangsu Province, Jiangsu College of Nursing, Huai'an, 223005, Jiangsu, P. R. China.
Shujun Gao *Department of Nuclear Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, P. R. China.
Zhanghui Li *Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P. R. China.
Lei Yin *Jiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P. R. China.
Shiyao GeJiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P. R. China.
Yangjing ZhaoJiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P. R. China.
Hui WangJiangsu Key Laboratory of Medical Science and Laboratory Medicine, Department of Immunology, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P. R. China. wanghui@ujs.edu.cn.
Bing WanDepartment of Respiratory and Critical Care Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, No. 169 Hushan Road, Jiangning, Nanjing, 210002, P. R. China. bingwan76@163.com.
Qixiang ShaoInstitute of Medical Genetics and Reproductive Immunity, The Digestive and Reproductive System Cancers Precise Prevention Engineering Research Center of Jiangsu Province, Jiangsu College of Nursing, Huai'an, 223005, Jiangsu, P. R. China. shao_qx@ujs.edu.cn.

Funding

Huai'an Natural Science Foundation HAB202217Innovation Team of Jiangsu College of Nursing SHCXTD 2023052901Leading Talents of Jiangsu College of Nursing 2021L001National Natural Science Foundation of China 81701545National Natural Science Foundation of China 8200183National Natural Science Foundation of China 82071738Natural Science Foundation of Jiangsu Province,China BK20231236Pre-research Fund Project of the Second Affiliated Hospital of Soochow University SDFEYJC2101Suzhou Science and Technology Development Project SKY2022154
6 · The paper itself

Abstract

BACKGROUND AND

objectiveHyperinflammatory response in early stage of sepsis was the key factor leading to multi-organ injury. Therefore, exploring an effective therapy to attenuate or reverse hyperinflammation was the priority of sepsis treatment. Previous study from our team showed that recombinant human interleukin-11 (rhIL-11) was a promising anti-inflammation cytokine in sepsis. However, the molecular mechanism was not fully elucidated. This study aims to evaluate the therapeutic potential of rhIL-11 in septic mice model and explore the underlying the molecular mechanism.

methodsA cecal ligation and puncture (CLP) model was applied to induce septic mice. Mice were separated into five groups with six animals in each group, including normal, sham, sham + rhIL-11, CLP and CLP + rhIL-11 groups. Therapeutic potential of rhIL-11 was evaluated by comparing body weight, survival time and liver damage (hematoxylin and eosin (H&E) staining, pro-inflammatory cytokines and serum measurements of liver enzymes). Hepatic myeloid-derived suppressor cells (MDSC) percentage was also compared. In vitro, MDSC differentiation from bone marrow (BM) cells was induced in the presence of appropriate stimuli, followed by the proportion and subsets analysis via flow cytometer. The related signal pathways including STAT3 and mTORC1 were detected by western blotting. The effect of MDSCs inhibition by STAT3 and mTORC1 inhibitors on septic mice was evaluated by comparing survival time, liver damage and MDSCs percentage.

resultsHere, we declared that early treatment of rhIL-11 exerted a liver protective effect and caused the expansion of monocytic myeloid-derived suppressor cells (M-MDSCs) in septic mice model. The results of in vitro studies declared that rhIL-11 promoted differentiation of BM cells into M-MDSCs phenotypically and functionally via activating STAT3 signaling, which was cross-regulated by the mTORC1. Furthermore, we also elucidated that mTORC1 bound directly to STAT3 through an interaction between raptor and TOS motif in STAT3. Finally, inhibition of mTORC1 or STAT3 in vivo blocked the differentiation of M-MDSCs and attenuated liver protective effect of rhIL-11.

conclusionsTaken together, these results suggested that early treatment of rhIL-11 in septic mice might reverse the hepatic damage at least in part by inducing the differentiation of M-MDSCs via STAT3 signaling pathway, and STAT3 signaling is modulated by a parallel branch of mTORC1.

Indexed as

Hepatic damageMonocytic myeloid-derived suppressor cells (M-MDSCs)mTORC1Recombinant human interleukin-11 (rhIL-11)SepsisSTAT3

Identifiers

PMID40500712
PMCPMC12160463

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.